Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14706244 | 0.87 | — | — | |
| SCHEMBL3179171 | 0.87 | — | — | |
| SCHEMBL14315628 | 0.86 | THRB (0.50) | THRBLMNA | |
| SCHEMBL9873559 | 0.84 | THRB (0.73) | THRBLMNA | |
| SCHEMBL868849 | 0.83 | THRB (0.71) | THRBLMNA | |
| SCHEMBL4694073 | 0.82 | THRB (0.46) | THRBLMNA | |
| SCHEMBL2202081 | 0.80 | THRB (0.43) | THRBLMNA | |
| SCHEMBL6477757 | 0.80 | THRB (0.43) | THRBLMNA | |
| SCHEMBL10413932 | 0.78 | ALDH1A1 (0.42) | THRB | |
| SCHEMBL5847043 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119230943-B | Sodium ion electrolyte suitable for high temperature and preparation method thereof | 天能电池集团股份有限公司 | 2025-04-11 | — | — | CN | claimed |
| WO-2025053792-A1 | COLLECTIVE SYNTHESIS OF PHANTOMOLIN FAMILY THROUGH TOTAL SYNTHESIS OF THE SESQUITERPENE LACTONE MOLEPHANTIN | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2025-03-13 | — | — | WO | claimed |
| CN-119230943-A | Sodium ion electrolyte suitable for high temperature and preparation method thereof | 天能电池集团股份有限公司 | 2024-12-31 | — | — | CN | claimed |
| US-20240141362-A1 | MODIFIED OLIGONUCLEOTIDES WITH INCREASED STABILITY | UNIV MASSACHUSETTS (US) | 2024-05-02 | — | — | US | claimed |
| EP-4279134-A1 | METHODS AND COMPOSTIONS FOR POTENTIATING THE ACTION OF OPIOID ANALGESICS USING IBOGA ALKALOIDS | DemeRx, Inc. (US) | 2023-11-22 | — | — | EP | claimed |
| US-11820985-B2 | Modified oligonucleotides with increased stability | UNIVERSITY OF MASSACHUSETTS (US) | 2023-11-21 | — | — | US | claimed |
| EP-3915639-B1 | METHODS AND COMPOSTIONS FOR POTENTIATING THE ACTION OF OPIOID ANALGESICS USING IBOGA ALKALOIDS | DEMERX INC (US) | 2023-06-07 | — | — | EP | claimed |
| CN-114096550-B | Modified nucleosides and methods of synthesis thereof | 斯微(上海)生物科技股份有限公司 | 2023-04-14 | — | — | CN | claimed |
| US-20220194972-A1 | Novel Process for Preparing Rhenium Chelated MAG3 Oligonucleotides | ROCHE INNOVATION CT COPENHAGEN AS (DK) | 2022-06-23 | — | — | US | claimed |
| EP-3962918-A1 | NOVEL PROCESS FOR PREPARING RHENIUM CHELATED MAG3 OLIGONUCLEOTIDES | Roche Innovation Center Copenhagen A/S (DK) | 2022-03-09 | — | — | EP | claimed |
| WO-1998022423-A1 | BI-AROMATIC COMPOUNDS, PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME AND USES | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) | 1998-05-28 | — | — | WO | claimed |
| EP-0828749-A1 | COMPOSITIONS AND METHODS FOR THE SYNTHESIS OF ORGANOPHOSPHORUS DERIVATIVES | GENTA INCORPORATED (US) | 1998-03-18 | — | — | EP | claimed |
| EP-0823903-A1 | HETEROCYCLIC DIARYL COMPOUNDS, PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME, AND USES THEREOF | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA, ( CIRD GALDERMA) (FR) | 1998-02-18 | — | — | EP | claimed |
| WO-1997029100-A1 | HETEROCYCLIC DIARYL COMPOUNDS, PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME, AND USES THEREOF | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) | 1997-08-14 | — | — | WO | claimed |
| WO-1996037503-A1 | COMPOSITIONS AND METHODS FOR THE SYNTHESIS OF ORGANOPHOSPHORUS DERIVATIVES | GENTA INCORPORATED (US) | 1996-11-28 | — | — | WO | claimed |
| EP-0732328-A1 | Aromatic heterocyclic compounds, pharmaceutical and cosmetic compositions containing them and their uses | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) | 1996-09-18 | — | — | EP | claimed |
| EP-0600161-A1 | Amino acid terminated polyesters having predetermined monomeric sequence | United States Surgical Corporation (US) | 1994-06-08 | — | — | EP | claimed |
| EP-0579173-A2 | Polyesters having predeterminated monomeric sequence | United States Surgical Corporation (US) | 1994-01-19 | — | — | EP | claimed |
| US-5256762-A | Polyesters having predetermined monomeric sequence | UNITED STATES SURGICAL CORPORATION (US) | 1993-10-26 | — | — | US | claimed |
| US-5248761-A | Amino acid terminated polyesters having predetermined monomeric sequence | UNITED STATES SURGICAL CORPORATION (US) | 1993-09-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220194972-A1 | Novel Process for Preparing Rhenium Chelated MAG3 Oligonucleotides | MAG, RTN3, RABL3 | THRB 3891/4885LMNA 3014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.